Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Rating of “Hold” from Analysts

Aardvark Therapeutics, Inc. (NASDAQ:AARD) has been given a consensus recommendation of “Hold” by the twelve ratings firms that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $15.33.

Several analysts have recently weighed in on AARD shares. Wall Street Zen upgraded shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $6.00 price target on shares of Aardvark Therapeutics in a research note on Thursday. HC Wainwright reissued a “neutral” rating and issued a $6.00 price target on shares of Aardvark Therapeutics in a research report on Monday, July 20th. Finally, Weiss Ratings upgraded shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 2nd.

Aardvark Therapeutics Stock Performance

Shares of NASDAQ AARD opened at $5.06 on Wednesday. Aardvark Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $17.94. The firm has a market capitalization of $110.71 million, a PE ratio of -1.58 and a beta of 3.74. The stock’s 50-day simple moving average is $6.16 and its 200-day simple moving average is $5.28.

Aardvark Therapeutics (NASDAQ:AARD) last posted its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.21. On average, sell-side analysts forecast that Aardvark Therapeutics will post -3.17 earnings per share for the current fiscal year.

More Aardvark Therapeutics News

Here are the key news stories impacting Aardvark Therapeutics this week:

• Neutral Sentiment: RBC Capital Markets maintained a Hold/Sector Perform view and a $6.00 price target, indicating limited expected upside from recent trading levels. RBC also said ARD-101’s development path could be challenging. Aardvark Therapeutics Gets a Hold from RBC Capital
• Negative Sentiment: Several firms announced or promoted a securities class action covering Aardvark’s February 2025 IPO and trading through May 14, 2026. The complaints allege investors were misled about ARD-101’s safety and efficacy, potentially creating legal costs, liability risk and reputational damage. Pomerantz Class Action Announcement
• Negative Sentiment: The most damaging allegation concerns cardiac safety: the complaint argues that company disclosures described ARD-101 as largely restricted to the gut and free of serious adverse events while failing to adequately disclose cardiac issues that later led to a full FDA clinical hold. If substantiated, the issue could delay development and increase financing risk. Hagens Berman AARD Investor Notice

Insider Buying and Selling at Aardvark Therapeutics

In related news, insider Nelson Sun sold 62,000 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $5.18, for a total value of $321,160.00. Following the completion of the sale, the insider directly owned 35,475 shares of the company’s stock, valued at $183,760.50. This represents a 63.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 17.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Aardvark Therapeutics in the second quarter valued at approximately $1,077,000. Renaissance Technologies LLC purchased a new position in shares of Aardvark Therapeutics during the first quarter worth approximately $267,000. Propel Bio Management LLC acquired a new position in shares of Aardvark Therapeutics in the 4th quarter valued at $609,000. J. Goldman & Co LP acquired a new position in shares of Aardvark Therapeutics in the 2nd quarter valued at $233,000. Finally, Ieq Capital LLC purchased a new stake in Aardvark Therapeutics in the 2nd quarter valued at $221,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing oral therapies for obesity, hyperphagia and related metabolic disorders. The company’s approach is based on activating bitter taste receptors, which it believes may influence appetite regulation and metabolic signaling without relying on injectable therapies.

Aardvark’s lead investigational product, ARD-101, is an oral small-molecule bitter taste receptor agonist being studied for conditions involving excessive hunger and food intake, including hyperphagia associated with Prader-Willi syndrome.